Consent Decree Looms As Philips Scores Q2 Growth In A Far From 'Business-As-Usual' Year

Embattled Healthtech Says Agile Operating Model And Restructuring Plans Remain On Track

Market uncertainties caused by macro events and the Respironics recall put their imprint on Philips’ second quarter of 2023, but the company secured high single-digit growth, reported robust order bookings and increased full-year revenue guidance.

Shutterstock

Royal Philips' CEO Roy Jakobs reported an improved operational performance for the healthtech and personal health company in the second quarter of 2023 − the third in a row – with comparable sales growth of 9%. The improvement was generated across all divisions and regions, he said.

The buoyancy was tempered, as has been the case for two years, by the Respironics recall and Philips’ remediation action....

Medtech Insight Podcast

Keep up with the top medtech business and regulatory news.

Medtech Insight brings you interviews and analysis, on the go.

More from Recalls

More from Policy & Regulation